多发性骨髓瘤的研究进展
Advances in Research on Multiple Myeloma
DOI: 10.12677/ACM.2022.12111462, PDF,  被引量   
作者: 管鑫鑫：黑龙江中医药大学，黑龙江 哈尔滨；刘松江*：黑龙江中医药大学附属第一医院，黑龙江 哈尔滨
关键词: 多发性骨髓瘤；蛋白酶抑制剂；免疫疗法；造血干细胞移植；综述；Multiple Myeloma； Protease Inhibitors； Immunotherapy； Hematopoietic Stem Cell Transplantation； Review
摘要: 多发性骨髓瘤是由于骨髓中的无性系浆细胞增生异常，所产生的单克隆抗体或M蛋白片段，会导致机体机能失调，从而导致相应的器官或组织损伤。多发性骨髓瘤的常见症状有：骨痛、病理性骨折、贫血、高钙血症、肾功能不全、免疫功能异常等。此外，还会出现淀粉样变性、高粘滞综合征、神经病变等。目前，关于多发性骨髓瘤的原因还不明确。本文就近年来有关多发性骨髓瘤的治疗进展进行综述。
Abstract: Multiple myeloma is caused by abnormal proliferation of asexual lineage plasma cells in the bone marrow, which produce monoclonal antibodies or M protein fragments that can lead to dysfunction of the body, resulting in damage to the corresponding organ or tissue. Common symptoms of multi-ple myeloma include bone pain, pathological fractures, anemia, hypercalcemia, renal insufficiency, and abnormal immune function. In addition, amyloidosis, hyperviscosity syndrome, and neuropa-thy may occur. At present, the causes of multiple myeloma are still unclear. In this article, we re-view the progress of treatment regarding multiple myeloma in recent years.
文章引用：管鑫鑫, 刘松江. 多发性骨髓瘤的研究进展[J]. 临床医学进展, 2022, 12(11): 10138-10145. https://doi.org/10.12677/ACM.2022.12111462

参考文献

[1] Walker, B.A., et al. (2018) Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple My-eloma. Blood, 132, 587-597. [Google Scholar] [CrossRef] [PubMed]
[2] Uamani, S.Z., Diel, J., Ito, T., Mehra, M., Khan, I. and Lam, A. (2017) Daratumumab Monotherapy Compared with Historical Control Data in Heavily Pretreated and Highly Refarctory Patients with Multiple Myeloma: An Adjusted Treatment Comparison. American Jour-nal of Hematology, 92, e146-e152. [Google Scholar] [CrossRef] [PubMed]
[3] 黄月华, 潘崚. 硼替佐米的作用机制、临床应用及其疗效研究进展[J]. 实用诊断与治疗杂志, 2008(4): 280-282.
[4] Guerrero-Garcia, T.A., Mogollon, R.J. and Castillo, J.J. (2017) Bortezomib in Plasmablastic Lymphoma: A Glimpse of Hope for a Hard-to-Treat Disease. Leukemia Research, 62, 12-16. [Google Scholar] [CrossRef] [PubMed]
[5] 索传健, 周嘉俊, 顾民, 谭若芸. 硼替佐米通过下调smad泛素化调节因子2拮抗TNF-α诱导的肾小管上皮细胞表型转分化[J]. 中华器官移植杂志, 2018, 39(4): 232-237.
[6] 钟启, 刘爽, 朱阳敏, 谭友平, 郑丽玲, 欧瑞明. 异环磷酰胺、多柔比星脂质体、地塞米松联合方案对复发/难治多发性骨髓瘤有无髓外浆细胞瘤患者的疗效对比[J]. 中国医师进修杂志, 2018, 41(4): 329-332.
[7] 王欢, 赵真, 张滔, 马清, 血液, 熊梅. 硼替佐米联合地塞米松治疗老年多发性骨髓瘤的疗效及对免疫抑制因子、免疫细胞水平的影响[J]. 海南医学院学报, 2017, 23(2): 232-235.
[8] 李俊, 刘英杰, 宋庆. 硼替佐米为主的化疗方案联合苯达莫司汀治疗多发性骨髓瘤的临床研究[J]. 中国实用医刊, 2020, 47(13): 95-99.
[9] Xu, M. (2017) Immunomodulatory Drugs (IMiDs) in Multiple Myeloma: Mechanism of Action and Clinical Implications. Boston University, Boston.
[10] Richardson, P.G., Weller, E., Lonial, S., et al. (2010) Lenalidomide, Bortezomib, and Dexamethasone Combination Therapy in Patients with Newly Diagnosed Multiple Myeloma. Blood, 116, 679-686. [Google Scholar] [CrossRef] [PubMed]
[11] Zhou, L., Yu, W., Jayabalan, D.S., et al. (2020) Caspase-8 In-hibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function. Frontiers in Cell and Developmental Biology, 8, Article 605989. [Google Scholar] [CrossRef] [PubMed]
[12] Zhou, L., Huang, X., Niesvizky, R., Pu, Z. and Xu, G. (2021) Caspase-8 Regulates the Anti-Myeloma Activity of Bortezomib and Lenalidomide. American Society for Pharmacology and Experimental Therapeutics, 379, 303-309. [Google Scholar] [CrossRef] [PubMed]
[13] Siegel, D., Martin, T., Nooka, A., et al. (2013) Integrated Safety Pro-file of Single-Agent Carfilzomib: Experience from 526 Patients Enrolled in 4 Phase II Clinical Studies. Haematologica, 98, 1753-1761. [Google Scholar] [CrossRef] [PubMed]
[14] Kuhn, D.J., Voorhees, P.M., Strader, J.S., et al. (2005) Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway against Pre-Clinical Models of Multiple Myeloma. Blood, 106, 1576. [Google Scholar] [CrossRef] 
[15] Bal, S., Landau, H., Shah, G., et al. (2020) Stem Cell Mo-bilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Bi-ology of Blood and Marrow Transplantation, 26, 1394-1401. [Google Scholar] [CrossRef] [PubMed]
[16] 罗涛, 夏海龙. 卡非佐米治疗多发性骨髓瘤的疗效及安全性的系统评价[J]. 中国实验血液学杂志, 2019, 27(6): 1887-1893. [Google Scholar] [CrossRef] 
[17] Richardson, P.G., Baz, R., Wang, M., et al. (2014) Phase 1 Study of Twice-Weekly Ixazomib, an Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma Pa-tients. Blood, 124, 1038-1046. [Google Scholar] [CrossRef] [PubMed]
[18] Kumar, S.K., Laplant, B., Roy, V., et al. (2015) Phase 2 Trial of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. Blood Cancer Journal, 5, e338. [Google Scholar] [CrossRef] [PubMed]
[19] Moreau, P., Masszi, T., et al. (2016) Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England Journal of Medicine, 374, 1621-1634. [Google Scholar] [CrossRef] 
[20] Hou, J., Jin, J., Xu, Y., et al. (2017) Randomized, Double- Blind, Placebo-Controlled Phase III Study of Ixazomib Plus Lenalidomide-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: China Continuation Study. Journal of Hematology & Oncology, 10, Article No. 137. [Google Scholar] [CrossRef] [PubMed]
[21] Kumar, S.K., Buadi, F.K., Betsy, L.P., et al. (2018) Phase 1/2 Tri-al of Ixazomib, Cyclophosphamide and Dexamethasone in Patients with Previously Untreated Symptomatic Multiple Myeloma. Blood Cancer Journal, 8, Article No. 70. [Google Scholar] [CrossRef] [PubMed]
[22] Richardson, P.G., Hofmeister, C.C., Rosenbaum, C.A., et al. (2018) Twice-Weekly Ixazomib in Combination with Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. British Journal of Haematology, 182, 231-244. [Google Scholar] [CrossRef] [PubMed]
[23] Spencer, A., Harrison, S., Zonder, J., et al. (2018) A Phase 1 Clinical Trial Evaluating Marizomib, Pomalidomide and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma (NPI-0052-107): Final Study Results. British Journal of Haematology, 180, 41-51. [Google Scholar] [CrossRef] [PubMed]
[24] Badros, A., Singh, Z., Dhakal, B., et al. (2017) Marizomib for Central Nervous System-Multiple Myeloma. British Journal of Haematology, 177, 221-225. [Google Scholar] [CrossRef] [PubMed]
[25] Carpenter, R.O., Evbuomwan, M.O., Pit Taluga, S., et al. (2013) B-Cell Maturation Antigen Is a Promising Target for Adoptive T-Cell Therapy of Multiple Myeloma. Clinical Cancer Research, 19, 2048-2060.
[26] Ali, S.A., Shi, V., Maric, I., et al. (2016) T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Multiple Myeloma. Blood, 128, 1688-1700.
[27] Zhao, W.-H., Liu, J., Wang, B.-Y., et al. (2018) A Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed against B Cell Maturation Antigen, in Patients with Relapsed or Refractory Multiple Myeloma. Journal of He-matology & Oncology, 11, Article No. 141.
[28] Drent, E., Themeli, M., Poels, R., et al. (2017) A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Molecular Therapy, 25, 1946-1958.
[29] Tang, F., Lu, Y., Ge, Y., Shang, J. and Zhu, X. (2020) Infusion of Chimeric Antigen Receptor T Cells against Dual Targets of CD19 and B-Cell Maturation Antigen for the Treatment of Refractory Multiple Myeloma. Journal of International Medical Research, 48, 112-119. [Google Scholar] [CrossRef] [PubMed]
[30] Levin, A.G., Slobodkin, M.R., Waks, T., et al. (2020) Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity. Cancer Immunology Research, 8, 1485-1495.
[31] Wang, X., Walter, M., Urak, R., et al. (2018) Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells against Multiple Myeloma. Clinical Cancer Research, 24, 106-119. [Google Scholar] [CrossRef] 
[32] 王芳侠, 李月, 曹星梅, 张王刚, 古流芳. 沙利度胺联合改良VAD方案治疗多发性骨髓瘤临床疗效观察[J]. 现代肿瘤医学, 2015, 23(17): 2495-2497.
[33] 朱小凤, 李晓明, 唐君玲. 沙利度胺片联合硼替佐米注射剂治疗老年多发性骨髓瘤患者的临床研究[J]. 中国临床药理学杂志, 2020, 36(15): 2225-2228. [Google Scholar] [CrossRef] 
[34] 唐雪娟, 任莉. 低剂量沙利度胺联合常规化疗治疗多发性骨髓瘤的临床分析[J]. 中国生化药物杂志, 2014, 34(4): 113-115.
[35] Barlogie, B. (2001) Introduction to Therapies in Multiple Myeloma. Seminars in Hematology, 38, 201-202. [Google Scholar] [CrossRef] 
[36] Moreau, P., Miguel, J.S., Sonneveld, P., et al. (2017) Multi-ple Myeloma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 28, iv52-iv61. [Google Scholar] [CrossRef] [PubMed]
[37] Dimopoulos, M.A., Sagar, L., Betts, K.A., et al. (2018) Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Fol-low-Up and Analysis of Relative Progression-Free Survival from the Randomized ELOQUENT-2 Trial. Cancer, 124, 4032-4043. [Google Scholar] [CrossRef] [PubMed]

为你推荐